Gufic Biosciences Limited is engaged in the manufacture of pharmaceuticals, medicinal chemicals and botanical products. Financial Results: Gufic BioSciences Ltd reported Revenues
Gufic Biosciences Limited
-(GUFICBIO)
XNSE:GUFICBIO, XBOM:GUFICBIO
Gufic BioSciences Ltd Q4FY24; 11% rise in Profits
Gufic Biosciences Limited is engaged in the manufacture of pharmaceuticals, medicinal chemicals and botanical products. Financial Results: Gufic BioSciences Ltd reported Revenues
Gufic BioSciences Ltd Q2FY24; 15% rise in Profits
Gufic Biosciences Limited is engaged in the manufacture of pharmaceuticals, medicinal chemicals and botanical products. Financial Results: Gufic BioSciences Ltd reported Revenues
Gufic Biosciences Limited Q2 FY24 Earnings Conference Call Insights
Key highlights from Gufic Biosciences Limited (GUFICBIO) Q2 FY24 Earnings Concall New Product Launches and Approvals Launched new products like Dalbavancin and
Gufic BioSciences: Advancements & Strategic Developments in Pharmaceuticals
“We are also happy to announce that Gufic has secured DCGI approval for the manufacturing and marketing of Dalbavancin and we are
Gufic BioSciences Ltd Q1FY24; 18% rise in Revenue
Gufic Biosciences Limited is engaged in the manufacture of pharmaceuticals, medicinal chemicals and botanical products. Financial Results: Gufic BioSciences Ltd reported Revenues
Gufic Biosciences Limited Q3 FY23 Earnings Conference Call Insights
Key highlights from Gufic Biosciences Limited (GUFICBIO) Q3 FY23 Earnings Concall Q&A Highlights: [00:11:06] Gunit Singh from CCIPL enquired about the driver
Gufic Biosciences Limited (GUFICBIO) Q3 FY23 Earnings Concall Transcript
Gufic Biosciences Limited (NSE:GUFICBIO) Q3 FY23 Earnings Concall dated Feb. 20, 2023. Corporate Participants: Ami Shah -- Company Secretary Avik Das -- Investor Relations D.B.Roonghta -- Chief Financial
Gufic Biosciences Limited (GUFICBIO) Q1 FY23 Earnings Concall
Gufic Biosciences Limited (NSE:GUFICBIO) Q2 FY23 Earnings Concall dated Nov.13, 2022 Corporate Participants: Ami Naresh Shah -- Company Secretary and Compliance Officer Avik Das -- Investor
Gufic Biosciences Limited Q1 FY23 Earnings Conference Call Insights
https://youtu.be/l4VNZKKcWGw Key highlights from Gufic Biosciences Limited (GUFICBIO) Q1 FY23 Earnings Concall Q&A Highlights: Girish Gulati asked about pancreatic cancer update and
Gufic Biosciences Limited Q3 FY22 Earnings Conference Call Insights
https://youtu.be/f3tlyxhD91U Key highlights from Gufic Biosciences Limited (GUFICBIO) Q3 FY22 Earnings Concall Management Update: In CDMO, GUFICBIO said it’s looking at a